Volume 21 Issue 6
Jun.  2023
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2023  >  21(6): 920-923
DU Meiling, CHU Yan, ZHANG Ziqiang, WEN Zhaoyang, TAO Yiran. Difference of Helicobacter pylori eradication rate between patients with atrophic gastritis and non-atrophic gastritis[J]. Chinese Journal of General Practice, 2023, 21(6): 920-923. doi: 10.16766/j.cnki.issn.1674-4152.003015
Citation: DU Meiling, CHU Yan, ZHANG Ziqiang, WEN Zhaoyang, TAO Yiran. Difference of Helicobacter pylori eradication rate between patients with atrophic gastritis and non-atrophic gastritis[J]. Chinese Journal of General Practice, 2023, 21(6): 920-923. doi: 10.16766/j.cnki.issn.1674-4152.003015
shu

Difference of Helicobacter pylori eradication rate between patients with atrophic gastritis and non-atrophic gastritis

doi: 10.16766/j.cnki.issn.1674-4152.003015
  • 1.

    Department of Gastroenterology, Fudan University Affiliated Shanghai Fifth People' s Hospital, Shanghai 200240, China

Funds:

 82002020

  • Received Date: 2023-03-26
    Available Online: 2023-08-26
    Abstract
  •   Objective  To investigate the difference of Helicobacter pylori (Hp) eradication rate between patients with atrophic gastritis and non-atrophic gastritis, and to analyze the relationship of the degree of gastric antrum atrophy, intestinal metaplasia and Hp density with Hp eradication rate.  Methods  A total of 505 Hp-positive patients who initially received amoxicillin combined with clarithromycin regimen in Fudan University Affiliated Shanghai Fifth People' s Hospital from January to December 2021 were enrolled and divided into two groups on the basis of pathological features in endoscopy, namely atrophic gastritis and non-atrophic gastritis. Propensity score matching (PSM) was used to reduce bias in the comparison of Hp eradication rates between two groups, followed by logistic regression analysis.  Results  After PSM, the failure rate of Hp eradication in atrophic gastritis group was significantly higher than that in non-atrophic gastritis group (16.3% vs. 7.8%, P=0.023), and the difference was significant in male (21.2% vs. 7.1%, P=0.008), but not in female (P > 0.05). Logistic regression analysis showed that the failure rate of Hp eradication was positively correlated with mild (pathological grade +) antral atrophy/intestinal metaplasia (OR=2.614, 95% CI: 1.227-5.571, P=0.013; OR=2.882, 95% CI: 1.310-6.338, P=0.009), but not associated with moderate to severe (pathological grade ++ to +++) antral atrophy/intestinal metaplasia (all P > 0.05). Moreover, Hp eradication failure was independent of antral Hp density (P > 0.05).  Conclusion  The failure rate of Hp eradication in patients with atrophic gastritis is significantly higher than that in patients with non-atrophic gastritis, and the difference is significant in males but not in females. In addition, Hp eradication failure increases only in patients with mild antral atrophy/intestinal metaplasia and doesn' t increase with the severity of antral atrophy/intestinal metaplasia. Moreover, Hp eradication failure is independent of antral Hp density.

     

    • FullText(HTML)
  • loading
    • References(25)
  • [1]
    ZAMANI M, EBRAHIMTABAR F, ZAMANI V, et al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection[J]. Aliment Pharmacol Ther, 2018, 47(7): 868-876. doi: 10.1111/apt.14561
    [2]
    REN S, CAI P, LIU Y, et al. Prevalence of Helicobacter pylori infection in China: a systematic review and meta-analysis[J]. J Gastroenterol Hepatol, 2022, 37(3): 464-470. doi: 10.1111/jgh.15751
    [3]
    张明伟, 汪建超, 王启之, 等. 安徽中南部地区幽门螺杆菌流行病学调查[J]. 中华全科医学, 2020, 18(8): 1395-1398. doi: 10.16766/j.cnki.issn.1674-4152.001516

    ZHANG M W, WANG J C, WANG Q Z, et al. Epidemiological investigation of Helicobacter pylori in central and southern area of Anhui province[J]. Chinese Journal of General Practice, 2020, 18(8): 1395-1398. doi: 10.16766/j.cnki.issn.1674-4152.001516
    [4]
    MALFERTHEINER P, MEGRAUD F, ROKKAS T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report[J]. Gut, 2022, 71(9): 1724-1762. doi: 10.1136/gutjnl-2022-327745
    [5]
    中华医学会消化病学分会幽门螺杆菌学组. 2022中国幽门螺杆菌感染治疗指南[J]. 中华消化杂志, 2022, 42(11): 745-756. doi: 10.3760/cma.j.cn311367-20220929-00479

    Helicobacter pylori Group, Chinese Society of Gastroenterology. 2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment[J]. Chinese Journal of Digestion, 2022, 42(11): 745-756. doi: 10.3760/cma.j.cn311367-20220929-00479
    [6]
    NYSSEN O P, BORDIN D, TEPES B, et al. European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients[J]. Gut, 2021, 70(1): 40-54. doi: 10.1136/gutjnl-2020-321372
    [7]
    NYSSEN O P, PEREZ-AISA A, CASTRO-FERNANDEZ M, et al. European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice[J]. United European Gastroenterol J, 2021, 9(1): 38-46. doi: 10.1177/2050640620972615
    [8]
    GU L, LI S, HE Y, et al. Bismuth, rabeprazole, amoxicillin, and doxycycline as first-line Helicobacter pylori therapy in clinical practice: a pilot study[J]. Helicobacter, 2019, 24(4): e12594. DOI: 10.1111/hel.12594.
    [9]
    YI D M, YANG T T, CHAO S H, et al. Comparison the cost-efficacy of furazolidone-based versus clarithromycin-based quadruple therapy in initial treatment of Helicobacter pylori infection in a variable clarithromycin drug-resistant region, a single-center, prospective, randomized, open-label study[J]. Medicine (Baltimore), 2019, 98(6): e14408. DOI: 10.1097/MD.0000000000014408.
    [10]
    QIAO C, LI Y, LIU J, et al. Clarithromycin versus furazolidone for naive Helicobacter pylori infected patients in a high clarithromycin resistance area[J]. J Gastroenterol Hepatol, 2021, 36(9): 2383-2388. doi: 10.1111/jgh.15468
    [11]
    郭涛, 王强, 吴晰, 等. 阿莫西林和克拉霉素的铋剂四联方案作为初次根除幽门螺杆菌治疗的1年随访结果[J]. 中国医学科学院学报, 2019, 41(1): 75-79. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYKX201901011.htm

    GUO T, WANG Q, WU X, et al. Amoxicillin-Clarithromycin-Containing bismuth quadruple therapy for primary eradication of Helicobacter pylori[J]. Acta Academiae Medicinae Sinicae, 2019, 41(1): 75-79. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYKX201901011.htm
    [12]
    房静远, 杜奕奇, 刘文忠, 等. 中国慢性胃炎共识意见精简版(2017年, 上海)[J]. 上海医学, 2017, 40(12): 705-708. https://www.cnki.com.cn/Article/CJFDTOTAL-SHYX201712001.htm

    FANG J Y, DU Y Q, LIU W Z, et al. Consensus on chronic gastritis in China(condensed edition)(2017, Shanghai)[J]. Shanghai Medical Journal, 2017, 40(12): 705-708. https://www.cnki.com.cn/Article/CJFDTOTAL-SHYX201712001.htm
    [13]
    DIXON M F, GENTA R M, YARDLEY J H, et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994[J]. Am J Surg Pathol, 1996, 20(10): 1161-1181. doi: 10.1097/00000478-199610000-00001
    [14]
    高文, 成虹, 胡伏莲, 等. 含艾普拉唑四联七天疗法根除幽门螺杆菌的全国多中心临床研究[J]. 中华医学杂志, 2012, 92(30): 2108-2112.

    GAO W, CHENG H, HU F L, et al. llaprazole based bismuth-containing quadruple regimen for the first-line treatment of Helicobacterpriori infection: a multicenter, randomized, controlled clinical study[J]. National Medical Journal of China, 2012, 92(30): 2108-2112.
    [15]
    LI B, LAN X, WANG L, et al. Proton-pump inhibitor and amoxicillin-based triple therapy containing clarithromycin versus metronidazole for Helicobacter pylori: a meta-analysis[J]. Microb Pathog, 2020, 142: 104075. DOI: 10.1016/j.micpath.2020.104075.
    [16]
    CHITAPANARUX T, KONGKARNKA S, WANNASAI K, et al. Prevalence and factors associated with atrophic gastritis and intestinal metaplasia: a multivariate, hospital-based, statistical analysis[J]. Cancer Epidemiol, 2023, 82: 102309. DOI: 10.1016/j.canep.2022.102309.
    [17]
    KALKAN I H, SAPMAZ F, GULITER S, et al. Severe gastritis decreases success rate of Helicobacter pylori eradication[J]. Wien Klin Wochenschr, 2016, 128(9-10): 329-334. doi: 10.1007/s00508-015-0896-2
    [18]
    GONI E, TAMMER I, SCHUTTE K, et al. The influence of gastric atrophy on Helicobacter pylori antibiotics resistance in therapy-naive patients[J]. Front Microbiol, 2022, 13: 938676. DOI: 10.3389/fmicb.2022.938676.
    [19]
    YU J, YANG P, QIN X, et al. Impact of smoking on the eradication of Helicobacter pylori[J]. Helicobacter, 2022, 27(1): e12860. DOI: 10.1111/hel.12860.
    [20]
    OZEKI K, FURUTA T, HADA K, et al. Relationship of the difficulty of Helicobacter pylori eradication with drinking habits and allergic disease[J]. Microorganisms, 2022, 10(5): 1029. DOI: 10.3390/microorganisms10051029.
    [21]
    LERTPIRIYAPONG K, WHARY M T, MUTHUPALANI S, et al. Gastric colonisation with a restricted commensal microbiota replicates the promotion of neoplastic lesions by diverse intestinal microbiota in the Helicobacter pylori INS-GAS mouse model of gastric carcinogenesis[J]. Gut, 2014, 63(1): 54-63. doi: 10.1136/gutjnl-2013-305178
    [22]
    张明君, 赵静, 梁晗玮, 等. 13C尿素呼气试验检测值的判读价值[J]. 临床内科杂志, 2022, 39(4): 246-250. https://www.cnki.com.cn/Article/CJFDTOTAL-LCLZ202204019.htm

    ZHANG M J, ZHAO J, LIANG H W, et al. Prognostic value of 13C-urea breath test[J]. Journal of Clinical Internal Medicine, 2022, 39(4): 246-250. https://www.cnki.com.cn/Article/CJFDTOTAL-LCLZ202204019.htm
    [23]
    MUKAISHO K, HAGIWARA T, NAKAYAMA T, et al. Potential mechanism of corpus-predominant gastritis after PPI therapy in Helicobacter pylori-positive patients with GERD[J]. World J Gastroenterol, 2014, 20(34): 11962-11965. doi: 10.3748/wjg.v20.i34.11962
    [24]
    ZHAO X, ZHANG Z, LU F, et al. Effects of CYP2C19 genetic polymorphisms on the cure rates of H. pylori in patients treated with the proton pump inhibitors: an updated meta-analysis[J]. Front Pharmacol, 2022, 13: 938419. DOI: 10.3389/fphar.2022.938419.
    [25]
    DEAN L, KANE M. Omeprazole Therapy and CYP2C19 Genotype[M]. Bethesda (MD): National Center for Biotechnology Information(US), 2012.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(7)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (173) PDF downloads(5) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return